Communiqués Telo Genomics Corp. Toronto S.E.

Actions

TELO

CA87975M1095

Cours en clôture Toronto S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^PTS	-.--%		-.--%	-.--%

12/06	Telo Genomics Corp. annonce les résultats du développement, de la validation et de la mise en œuvre de ses modules d'apprentissage automatique et d'intelligence artificielle, utilisés dans ses tests de diagnostic du myélome TeloView	CI
28/05	Telo Genomics Corp. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP	18/06	NE
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024	12/06	NE
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology	30/05	NE
Telo Genomics and Emery Pharma Announce Collaboration	15/05	NE
Telo Genomics Receives Accreditation from College of American Pathologists	10/04	NE
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial	02/04	NE
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients	13/02	NE
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US	30/01	NE
Telo Genomics Gears up for American Society of Hematology Conference	06/12	NE
Telo Genomics Launches Physician Experience Program in the United States	16/11	NE
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists	07/11	NE
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting	01/11	NE
Telo Genomics : Consolidated Financial Statements	30/10/23	PU
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation	26/10/23	NE
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved	17/10/23	NE
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting	12/10/23	NE
Telo Genomics Completes Oversubscribed Private Placement	15/06/23	AQ
Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting	14/04/23	AQ
Telo Genomics : Q1 - 2023	17/11/22	PU
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board	19/10/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Telo Genomics Corp. Toronto S.E.

Actions

TELO

CA87975M1095

Communiqués

Filtres